Keyphrases
In Situ Hybridization
100%
CCNE1
100%
Type II Endometrial Cancer
100%
Endometrial Cancer
83%
Cyclin E1
50%
OncoScan
33%
P53 Expression
33%
Genomic DNA (gDNA)
16%
Bright-field Microscopy
16%
Biomarker Testing
16%
Anticancer Therapy
16%
Molecular Pathology
16%
Therapeutic Response
16%
Histological Subtypes
16%
FIGO Stage
16%
Response to Chemotherapy
16%
Prospective Clinical Trial
16%
Robust Biomarker
16%
Pathological Parameters
16%
Copy number
16%
Gene Copy number Variation
16%
Cyclin-dependent Kinase Inhibitor
16%
Protein Expression Analysis
16%
Non-endometrioid
16%
Hybridization number
16%
Copy number Profiling
16%
Medicine and Dentistry
Uterine Cancer
100%
In Situ Hybridization
100%
Proliferating Cell Nuclear Antigen
37%
Protein P53
25%
Biological Marker
12%
Protein Expression
12%
Clinical Trial
12%
Prevalence
12%
Cancer Treatment
12%
Genomic DNA
12%
Treatment Response
12%
The Cancer Genome Atlas
12%
Molecular Pathology
12%
Bright Field Microscopy
12%
Expression Analysis
12%
Cyclin Dependent Kinase Inhibitor
12%
Gene Dosage
12%
Biochemistry, Genetics and Molecular Biology
In Situ Hybridization
100%
Cyclin E1
50%
P53
33%
Clinical Trial
16%
Anticancer
16%
Expression Analysis
16%
Gene Dosage
16%
Prevalence
16%
Protein Expression
16%
Cyclin-Dependent Kinase
16%
Genomics
16%
Pharmacology, Toxicology and Pharmaceutical Science
Endometrium Cancer
100%
Cycline
37%
Protein P53
25%
Clinical Trial
12%
Chemotherapy
12%
Malignant Neoplasm
12%
Prevalence
12%
Biological Marker
12%
Genomic DNA
12%
Cyclin Dependent Kinase Inhibitor
12%
Molecular Pathology
12%